BioDlink Clarifies Pre-IPO Share Option Scheme and Expiry in Supplemental Annual Report

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an announcement.

BioDlink International Company Limited has issued a supplemental announcement to its 2024 annual report, providing additional details on its Pre-IPO Share Option Scheme and related equity incentive plans as required under Hong Kong listing rules. The company disclosed that up to 16,969,000 shares, representing about 2.20% of its issued share capital at the annual report date, may be issued under the Pre-IPO scheme, clarified eligibility (employees and former employees acting as consultants), vesting conditions tied to seniority and R&D milestones, option exercise procedures, and the pricing mechanism, including adjustments for changes in share capital and dividends. It also confirmed that the grant period for the Pre-IPO scheme has expired, meaning no new options can be issued under it, signaling a shift toward its newer restricted share award schemes and offering investors greater transparency on dilution and long-term incentive alignment with the company’s research-focused performance targets.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

More about TOT BIOPHARM International Co. Ltd.

BioDlink International Company Limited is a Hong Kong-incorporated company listed on the Main Board of the Hong Kong Stock Exchange. The group operates in the biopharmaceutical sector, focusing on research and development of drug candidates, with a workforce that includes employees and consultants supporting its R&D-driven operations.

Average Trading Volume: 188,450

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.93B

Find detailed analytics on 1875 stock on TipRanks’ Stock Analysis page.